ALNY Q3 2021 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$188M+49.1% YoY

Gross Profit

$155M82.6% margin

Operating Income

-$182M-96.8% margin

Net Income

-$205M-109.0% margin

EPS (Diluted)

$-1.72

QoQ Revenue Growth

-14.9%

Cash Flow

Operating Cash Flow

-$134M

Free Cash Flow

-$160M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$2.7B

Stockholders' Equity

$756M

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$188M	$126M	+49.1%
Gross Profit	$155M	$104M	+48.9%
Operating Income	-$182M	-$225M	+19.3%
Net Income	-$205M	-$253M	+19.3%

Revenue Segments

Product

$167M100%

Royalty

$453,0000%

Geographic Segments

Non-US Or Europe

$18M55%

Europe

$10M29%

UNITED STATES

$5M16%